Please ensure Javascript is enabled for purposes of website accessibility

Why Akcea Therapeutics Rocketed Higher Today

By Brian Orelli, PhD - May 11, 2018 at 12:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An FDA advisory committee endorsed the biotech's lead drug, but an approval is far from a slam dunk.

What

Shares of Akcea Therapeutics (AKCA) are up 13% at 11:33 a.m. EDT today after the Food and Drug Administration's Metabolism and Endocrinology Products Advisory Committee voted 12-8 recommending the approval of Waylivra for a rare genetic disease called familial chylomicronemia syndrome (FCS). As typically happens for smaller biotechs, shares of Akcea were halted yesterday since the meeting was likely to cause volatility.

Ionis Pharmaceuticals (IONS 0.23%), Akcea's majority owner and the developer of Waylivra, is up 4.4% on the news as well.

So what

A 12-8 vote isn't exactly a ringing endorsement, but it was pretty clear from the FDA documents for the committee, which were publicly posted on Tuesday, that the agency reviewers were torn between the efficacy and safety of Waylivra, which also goes by the generic name volanesorsen. Patients with FCS have elevated levels of triglycerides (TG), which Waylivra clearly helps reduce, but the drug is also associated with thrombocytopenia, or low blood platelet levels.

Three blood vials lying on top of diagnostic test order form

Image source: Getty Images.

"Despite the magnitude of the effect observed on TG, the volanesorsen review team remains uncertain whether the benefits of volanesorsen outweighs its risks, considering safety concerns with this product," James Smith, the FDA's deputy director of the division of metabolism and endocrinology products, wrote in the briefing documents.

Those documents sent shares of Akcea and Ionis down on Tuesday. Nonetheless, both companies are trading higher today than they were when the week started, which seems reasonable given the committee's endorsement.

Now what

An approval is by no means a slam dunk at this point. The FDA gets to make the final decision and doesn't have to follow the committee's recommendation. Given the eight dissenting votes, it's clear the committee was as conflicted as the FDA reviewers.

Adding to the issues, Akcea has proposed changing the dosing of the drug and monitoring for thrombocytopenia compared to what was done in the clinical trial. The FDA may end up rejecting the drug, asking the company to test its proposal in a new clinical trial to see if it can reduce the incidence of the side effect.

Investors won't have to wait too long to find out whether Waylivra will be approved. The FDA plans to decide by Aug. 30.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akcea Therapeutics, Inc. Stock Quote
Akcea Therapeutics, Inc.
AKCA
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$39.34 (0.23%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.